2011
pubmed
5 citations
Tesamorelin.
Grunfeld. Carl C; Dritselis. Argyris A; Kirkpatrick. Peter P
Key Findings
- Error
Practical Outcomes
- Error
Summary
Error: Timeout.
Abstract
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Study Information
Provider
pubmed
Year
2011
Date
2011-02-01T00:00:00.000Z
DOI
10.1038/nrd3362
Citations
5
References
14